Innovative Medicine: Expects slightly stronger sales growth in the first half of the year compared to the second. Sees continued uptake from recently launched products. Anticipates entry of Stelara biosimilars in Europe towards the middle of the year. MedTech: Operational sales growth expected to be relatively consistent throughout the year. Expects 2024 procedure volumes to remain above pre-COVID levels. Sees modest impact from Russia sanctions in first half of the year. Sees VBP pricing for Surgical IOLs and Sports in 2024; lapping of 2023 VBP impacts throughout the year. P&L: EPS growth will benefit from 191M share reduction in the first half of the year; partial benefit in Q3. Comments taken from investor presentation slides for Q1 earnings conference call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
